ArticleDermatology and therapy2024

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA).

Kristian Reich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.